<DOC>
	<DOCNO>NCT00984113</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics safety elinogrel metabolite patient mild , moderate , severe renal impairment compare healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetics Elinogrel Healthy Volunteers Patients With Mild , Moderate , Severe Renal Impairment</brief_title>
	<detailed_description>Multiple-dose , open-label parallel-group design patient mild , moderate severe renal impairment age ( ±7 year ) , sex weight ( ±15 % BMI ) match healthy subject . - mild renal impairment : CrCl 50 ≤80 ml/min - moderate renal impairment : CrCl 30 &lt; 50 ml/min - severe renal impairment : CrCl &lt; 30 ml/min</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Able understand sign write informed consent Subjects either normal renal function stable renal disease History heart disease Unstable clinically significant disorder respiratory , hepatic , metabolic , psychiatric gastrointestinal disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Elinogrel</keyword>
	<keyword>Renal impairment</keyword>
	<keyword>Healthy</keyword>
	<keyword>Kidney dysfunction</keyword>
</DOC>